The Essential Need for Trust When Transmission Risk Cannot Be Eliminated in HIV-Remission Trials.

Analytic treatment interruption (ATI) is scientifically necessary in HIV-remission ("cure") studies to test the effects of new interventions. However, stopping antiretroviral treatment poses risks to research participants and their sexual partners. Ethical debate about whether and how to conduct such studies has largely centered on designing risk-mitigation strategies and identifying the responsibilities of research stakeholders.

Viral Blips After Treatment Initiation During Acute Human Immunodeficiency Virus Infection.

Transient viral blips ≥20 copies/mL were observed in 16.9% of acutely treated adults with HIV. Blip incidence increased from 0.

The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children.

Background: HIV-infected children have high risk of invasive pneumococcal disease (IPD) despite receiving highly active antiretroviral therapy (HAART). This study aimed to determine the immunogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV-7) in Thai HIV-infected children compared to HIV-exposed uninfected children.

Methods: A prospective study was conducted among children 2 months to 9 years.

Henoch-Schönlein purpura and thrombocytopenia after planned antiretroviral treatment interruption in a Thai girl with HIV infection.

A handful of Henoch-Schönlein purpura (HSP) cases have been reported in HIV-infected adult patients. We report herein the case of an 11-year-old Thai girl with HIV infection, who developed severe abdominal pain and palpable purpura consistent with HSP, 3 months after planned antiretroviral treatment interruption (PTI). One month later she developed thrombocytopenia.